Some series of blood pressure medications have been recalled due to the fact that they actually have all the chances to keep the admixture of attorneys, in fact that caused cancer, the FDA USA announced Tuesday.

Some Irbesartan pills manufactured ScieGen medicinal and marked as Westminster and pharmaceutical Golden state medical equipment, Inc (shareholders) is dependent on volunteer feedback.

The FDA talks densely clenched products are reminded because of the presence of an impurity: N-nitrosodiethylamine (NDEA). According to the FDA, the international Agency for research on cancer lists this substance as a possible human carcinogen.

The FDA has published an absolute list of performed large number of medications that have been implemented in 75 mg, 150 mg and 300 mg doses. 

For patients who find their drug between withdrawn batches, the FDA advises to address the pharmacist or doctor about another cure. Patients must continue to take their own medications as long as you're not going to cooperated other healing, such as immediate stop has the ability to be more malicious, talking FDA.

NDEA " happens of course in some foods, drinking water, air pollution and industrial processes," the FDA talks. 

Prescribed, in fact that Irbesartan treats the highest blood pressure and has the ability to be used for such in order to treat kidney disease in some patients, according to the publication of the state library of medicine of the United States.

As of Tuesday's release, ScieGen Pharmaceuticals was not aware of any not-so-favorable recall-related activities, the FDA reports. 

in October. 26, the FDA announced that Aurobindo Pharma limited recalled 22 batches of Irbesartan that were sent to ScieGen pharmaceuticals Inc. USA for the manufacture of finished product Irbesartan.

Irbesartan's review follows in the footsteps of similar in August for the cardiac product valsartan.